

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

VOLUNTARY ANNOUNCEMENT

MemoCarna® OXIDE FILM SINGLE-RIVET PATENT FORAMEN OVALE OCCLUDER PRODUCT OBTAINS MEDICAL DEVICE REGISTRATION CERTIFICATE

The board of directors (the “**Board**”) of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) is pleased to announce that Shanghai Shape Memory Alloy Co., Ltd.# (上海形狀記憶合金材料有限公司), a wholly-owned subsidiary of the Company, has obtained a medical device registration certificate granted by the National Medical Products Administration of the People's Republic of China for the MemoCarna® Oxide Film Single-Rivet Patent Foramen Ovale Occluder Product (MemoCarna®氧化膜單鉚卵圓孔未閉封堵器) (the “**Product**”) (Registration Certificate No.: Guo Xie Zhu Zhun 20263132087).

Patent foramen ovale (“**PFO**”) is usually asymptomatic, but severe patency may have a variety of clinical manifestations, with cryptogenic stroke and migraine being the most common, and is one of the important causes of cryptogenic stroke. Transcatheter occlusion is an important treatment option for PFO, while post-operative residual shunt remains a clinical concern. Publicly available research shows that the incidence of residual shunt after PFO occlusion is approximately 10% to 30%, and is associated with an increased risk of recurrent stroke.

The Product, which was developed by the Company in-house, adopts an “M+W” interlocking and buckle-in disc design with a single-rivet recessed configuration, a concealed waist structure and a three-layer flow-blocking membrane design, so as to enhance the stability of occlusion and reduce nickel ion release. It is also available in nine models to accommodate the PFO occlusion needs of different anatomies, thereby effectively reducing post-occlusion residual shunts and improving the procedural success rate.

Together with the MemoSorb® Biodegradable Patent Foramen Ovale Occluder Product, for which the Company had previously obtained a medical device registration certificate, the marketing approval of the Product further enriches the Company's product portfolio in the field of PFO occlusion treatment, providing interventional treatment options with different technological approaches for clinical practice.

Looking ahead, the Company will continue to focus on the field of interventional treatment for structural heart disease, and keep advancing product development and clinical application to provide more treatment options for patients.

The sales performance of the Product will be subject to a number of factors including but not limited to clinical promotion, channel expansion, changes in competitive landscape and macro policies, in which there exist uncertainties of the Product on the Company's financial performance.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
October 12, 2026

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director; Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors; and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.".*

For identification purposes only.